Nigeria drug market situation

In recent years, Nigeria's pharmaceutical market has been expanding rapidly, with annual growth exceeding 9%, according to Pharma West Africa. Of the country's total healthcare expenditure of $10 billion, approximately $4 billion is allocated to pharmaceuticals.

According to a message released by the Nigerian Food and Drug Administration (NAFDAC) in October 2025, Nigeria's dependence on imported medicines has decreased from 70% to 60%, mainly sourced from India and China. Due to limited medical insurance coverage, out-of-pocket expenses account for 62% of total healthcare expenditures in Nigeria.

According to customs data statistics, the import value of Nigeria's Western medicine products in 2024 was $1.14 billion, with the main source countries being: India ($380 million, accounting for 33.3%), China ($310 million, accounting for 27.4%), the Netherlands ($50 million, accounting for 4.3%), the United Arab Emirates ($40 million, accounting for 3.7%), and France ($40 million, accounting for 3.1%).

2. Drug distribution channels in Nigeria market

Currently, Nigeria's limited public healthcare resources struggle to adequately meet the medical needs of its population. According to the Society for Family Health Nigeria, at least 70% of Nigerians access healthcare through private channels, including community pharmacies, retail pharmacies, and nearly 200,000 patent and proprietary medicine vendors (PPMV). These PPMVs are individuals without formal pharmaceutical training who sell over-the-counter medications.

To address the issue of drug accessibility, the Ministry of Health in Nigeria has established PPMVs as a category of retailer, aimed at providing over-the-counter medicines to poor rural communities. Nigerian law limits their services to pre-packaged medicines, but many PPMVs go beyond these restrictions.

3. Situation of the pharmaceutical manufacturing industry in Nigeria

Nigeria is experiencing rapid population growth and high poverty rates, resulting in significant unmet demand for essential medications. Consequently, the country's over 1,300 pharmaceutical companies primarily focus on treating common diseases. Analgesics, anti-rheumatic drugs, and antipyretics account for approximately 25% of the industry, while antibioticshttps://www.jxserum.com/hot-product-list/ and anti-infective drugs, multivitamins and tonics, and antimalarials each represent around 15%.

The top 10 pharmaceutical companies in Nigeria are as follows:

Nigeria's regulatory landscape

The drug regulator in Nigeria is the National Food and Drug Administration (NAFDAC), which regulates the manufacture, import and export, advertising, sale and use of food, drugs, cosmetics, medical devices, chemicals and water packaging.

The Pharmacy Council of Nigeria (PCN), the government body responsible for regulating pharmacies (including PPMVs), lacks sufficient funding, personnel, and capacity to effectively oversee all retail channels.

1

Drug registration and regulation

Under NAFDAC requirements, foreign manufacturers must register their medicines through a local representative (a Nigerian entity or individual).

(a) Set up a local subsidiary in Nigeria to register its products with NAFDAC;

(b) Appoint an existing Nigerian company (such as its local distributor) as its local representative in Nigeria;

(c) Engaging a custodial services company to manage product registration. This option is typically adopted by foreign manufacturers who prefer not to appoint local distributors as their representatives or go through the hassle of registering a company in Nigeria solely for product registration. The custodial services company provides services including maintaining NAFDAC registration under its own name and issuing a "no objection letter" to facilitate distributors' import of registered products into the Nigerian market.

In Nigeria, the official processing period for drug registration is 120 working days from the date of application submission. However, the registration process often encounters unexpected challenges, such as delayed submission of required information or documents, or objections arising during the process. As a result, the actual duration of the drug registration process is typically longer. The NAFDAC drug registration certificate is valid for 5 years, and the renewal period is also 5 years.

The specific drug registration process is as follows:

1. Fee Payment and Form Collection: Pay the fee via bank transfer and receive the individual product application form.
2. Submission materials: Fill out the application form and attach 6 types of documents:

Notarized manufacturer authorization letter (specifying product name and registration authorization);

Manufacturer and free sales certificate confirmed by the Nigerian Embassy;

The applicant's Nigerian corporate registration certificate;

Application for Import License of Samples;

Invitation for GMP inspection at overseas factories;

Product formula and other technical data.

3. Local clinical trial: after payment, the trial is conducted at an NAFDAC accredited facility
4. Payment of import license fees: Payment of the import license fee for medicines/herbs via bank.
5. Submit technical documentation: including complete product formulation information, which must comply with WHO CTD format standards.
6. Payment for laboratory evaluation: After document approval, the relevant evaluation fees must be paid.

7.GMP Inspection: NAFDAC inspectors conduct GMP compliance inspections on production facilities of overseas manufacturers.

8. Approval and Registration Announcement: Upon receipt of the qualified laboratory report, the registration and announcement approval process will be completed.
9. Pay the registration fee: The final fee is paid after approval.

2

Counterfeit Drug Control and International Cooperation

Counterfeit drugs remain a critical challenge for Nigeria. Since its establishment, the National Anti-Counterfeit Drug Agency (NAFDAC) has strengthened regulatory capacity and trained personnel to regulate the pharmaceutical market. Under NAFDAC's sustained efforts, the detection of counterfeit drugs has seen significant improvement. Over the past two years, the Nigerian government has destroyed approximately 220 billion naira worth of substandard and banned medications.

On May 8, 2025, the National Association of Pharmacist Distributors and Commissions (NAFDAC) and the Pharmaceutical Council of Nigeria (PCN) initiated the PIC/S pre-qualification application process, and received the written feedback from PIC/S on August 15,2025.

Nigeria's investment environment

Nigeria is the largest pharmaceutical market in West Africa, serving as China's third-largest trading partner and export market in the African pharmaceutical sector.

It has become the first choice of Chinese enterprises to dig deep in Africa.

Nigeria's business and policy environment presents a dual nature. While the market demonstrates high openness with low entry barriers and accommodative policies, it also faces challenges including underdeveloped infrastructure, inconsistent policy implementation, and deficiencies in government efficiency, oversight, and enforcement capabilities. Companies should conduct thorough research on local policies and market conditions before establishing operations to ensure smooth pharmaceutical distribution post-production.

Hydropower supply capacity:

Nigeria's underdeveloped power sector has become a major bottleneck for its economic growth. The country has 11 regional power distribution companies, each operating in its own area with varying electricity pricing. Moreover, Nigeria's overall power supply capacity and stability are inadequate, forcing businesses to rely on generators to maintain normal operations.

Water supply is tight and prices vary across Nigeria, and the well is a useful supplement to municipal water supply.

human resources ：

Nigeria is the most populous country in Africa and has a large pool of ordinary workers, but they need to be trained for a long time to meet the needs of the job.

business environment ：

The Nigerian Investment Promotion Board Act (2004), enacted in 1995, abolished controls and restrictions on foreign direct investment, allowing foreign investors to establish wholly-owned manufacturing facilities in pharmaceutical production sectors excluding narcotic and psychotropic drugs.

To attract foreign investment, the Nigerian government has designated chemical and pharmaceutical manufacturing as priority industries for development, offering them preferential policies. Under Nigerian law, while the corporate income tax rate is 30% for sectors other than oil and gas, these priority industries enjoy a 5-year tax exemption, which can be extended to 7 years in less developed regions.

With its strategic geographical position and favorable business environment, Nigeria has emerged as a key destination for Chinese pharmaceutical companies seeking investment and financing opportunities in Africa. A notable example is the September 2024 agreement between Jiangsu Aidi Pharmaceutical, the China-Africa Development Fund, and Nigeria's Fidson Pharmaceuticals to establish a joint venture pharmaceutical plant in Lagos, specializing in HIV and malaria drug production. The project has received special support under Nigeria's President's Pharmaceutical Value Chain Initiative (PVAC), benefiting from tax incentives and land allocation advantages.

Nigeria's import and export of pharmaceuticals

Nigeria's pharmaceutical production primarily serves domestic needs, with limited exports to West African countries including Ghana, Niger, and Sierra Leone. The products mainly consist of antipyretics, analgesics, antimalarials, antibiotics, antiretroviral drugs, and vitamins. However, due to constraints in local production capacity, the country still relies heavily on imported medications to meet domestic demand.

1

enter port

According to customs data statistics, Nigeria imported approximately $1.14 billion worth of Western pharmaceutical products in 2024, a year-on-year decrease of 5.0%, with the main source countries being India (approximately $380 million, accounting for 33.3%) and China (approximately $310 million, accounting for 27.4%). In the first quarter of 2025, Nigeria imported approximately $260 million worth of Western pharmaceutical products, a year-on-year increase of 2.1%, with the main source countries being India (approximately $98 million, accounting for 37.1%) and China (approximately $99 million, accounting for 37.6%).

Source: Medical Insurance Chamber of Commerce based on customs data

2

export

Customs data shows Nigeria exported pharmaceutical products worth approximately $1.04 million in 2024, with the majority of exports destined for African countries. Key destinations included West African nations such as Ghana ($274,000,26.5%), Sierra Leone ($102,000,9.9%), and Niger ($90,000,8.7%), along with the Central African country Chad ($196,000,18.9%).

In the first quarter of 2025, Nigeria exported pharmaceutical products worth approximately $201,000, representing a 13.5% year-on-year increase. The top five export markets were Ghana ($58,000,28.8%), Niger ($52,000,25.6%), Angola ($36,000,18.0%), India ($28,000,13.9%), and Liberia ($18,000,8.9%).

Nigeria, Ghana, Niger and other countries are members of the Economic Community of West African States (ECOWAS). According to the ECOWAS Trade Liberalization Plan, medicines as basic medical supplies enjoy zero tariff treatment in the region, which promotes the export of Nigerian medicines to neighboring regions to a certain extent.

China's export of Western medicine products to Nigeria

Source: China Medical Insurance Chamber of Commerce based on customs data

Customs statistics indicate that China's pharmaceutical trade with Nigeria is predominantly export-oriented. In 2024, China's exports of Western pharmaceutical products to Nigeria reached $390 million, marking a 13.2% year-on-year increase. Specifically, raw materials for Western medicines accounted for approximately $200 million, up 31% year-on-year; finished drugs amounted to $150 million, down 5.4%; while biochemical drugs totaled $40 million, representing a 20.2% growth.

In the first three quarters of 2025, China's exports of Western pharmaceutical products to Nigeria reached approximately $360 million, marking a 33.4% year-on-year increase and signaling the market's stabilization. Specifically, raw materials for Western medicines accounted for $180 million ($23.6% growth), finished drugs for $150 million ($45.1% growth), and biochemical drugs for $30 million ($42.1% growth), demonstrating the Nigerian market's robust vitality.

sum up

The Nigerian market continues to demonstrate strong demand for essential medicines. In its 2025 strategic plan, NAFDAC emphasized the need to prioritize pediatric antimalarial drugshttps://www.jxserum.com/hot-product-list/ and antibiotics, encouraging manufacturers to develop child-friendly medications. While maintaining robust prevention and control measures for major infectious diseases, demographic shifts and lifestyle changes have led to rising prevalence of chronic conditions like diabetes, cardiovascular diseases, and cancer in Nigeria, driving growing demand for chronic disease medicationshttps://www.jxserum.com/vaccines-biologicals/. Notably, generic drugs offer more affordable treatment options that align with local affordability, making the generic and biosimilar drug markets particularly promising.

At the level of international cooperation, on one hand, China helps local Nigerian pharmaceutical companies improve their production processes and quality control systems through technology transfer, enabling them to integrate into the global market. On the other hand, Chinese pharmaceutical companies leverage their supply chain advantages to provide Nigeria with raw materials and production equipment support, helping it establish an independent drug production chain covering chronic diseases, reducing its reliance on imports, and opening up new avenues for Sino-Nigerian pharmaceutical cooperation in the field of chronic diseases, achieving mutual benefits and win-win outcomes.